<DOC>
	<DOCNO>NCT00669097</DOCNO>
	<brief_summary>This phase l study examine Absorption , Distribution , Metabolism Excretion TKI258 . There 2 cohort . Cohort 1 ( 4 patient ) receive single radio-labeled 500mg dose TKI258 follow 15 day daily dose 400mg TKI258 . Cohort 2 ( 9 patient ) receive 400mg TKI258 .</brief_summary>
	<brief_title>Absorption , Distribution , Metabolism Excretion ( ADME ) Study TKI258 Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Aged ≥ 18 year 2 . Patients histologically confirm solid tumor lymphoma resistant/refractory approve therapy appropriate therapy available . 3. WHO performance status ≤ 2 4 . All previous treatment ( include surgery radiotherapy ) must complete least four week prior study entry acute toxicity must resolve 5 . Written inform consent participate study Exclusion criterion : 1 . Primary Brain Tumors symptomatic leptomeningeal metastases 2 . Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start 3 . Fertile male willing use contraception whose female partner use adequate contraceptive protection Pregnant lactate woman ( woman childbearing potential must negative pregnancy test ( &gt; 5 mIU/ml ) inclusion study ; postmenopausal woman must amenorrheic least 12 month ) . Female patient must use adequate contraceptive protection 4 . Centrally locate squamous cell carcinoma lung 5 . Proteinuria &gt; 1+ dipstick test 6 . History gastrointestinal malabsorption Surgery involve intestinal anastomosis within four week study start . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>ADME</keyword>
	<keyword>TKI258</keyword>
	<keyword>RTKs inhibitor</keyword>
	<keyword>PDGRF inhibitor</keyword>
	<keyword>VEGFER inhibitor</keyword>
</DOC>